Skip to content
value.today

Circular Genomics Inc.

🇺🇸 Albuquerque, New Mexico, USABiotechnologyFounded 2021
Total raised
$13 M
3 rounds on record
Latest round
$8 M
Jan 2024
First round on record
Aug 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Circular Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$8 MNo. 3$2 to $10 million

Circular Genomics Inc.: Raise no. 3, Jan 2024

Investors in this round

9 investors had bought by the notice of Jan 23, 2024: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $15 M offered; $7 M still to sell
Smallest investment taken
$99,999
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Sargeant · Executive Officer, Director
  • David Blivin · Director
  • Fortunado Rocca · Director
  • Joseph Cook III · Director
  • Nikolaos Mellios · Director
  • Waneta Tuttle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Sargeant, Manager. Source: SEC Form D, newest notice filed Jan 23, 2024. Read the notice at the SEC.

equitySEC
Nov 2021$3 MNo. 2$2 to $10 million

Circular Genomics Inc.: Raise no. 2, Nov 2021

Investors in this round

7 investors had bought by the notice of Mar 9, 2023: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$850,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Hafez · Executive Officer, Director, Promoter
  • Nikolaos Mellios · Executive Officer, Director, Promoter
  • Paul Sargeant · Executive Officer, Director
  • Stephen McKernan · Executive Officer
  • Blivin David · Director
  • Cathy Petti · Director
  • Fortunado Rocca · Director
  • Joseph Cook III · Director
  • Waneta Tuttle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to amounts sets forth above, $1,288,825 in outstanding convertible indebtedness was converted into equity securities in connection with the initial sale of securities in the offering.”

Signed by Paul Sargeant, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Mar 9, 2023. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$1 MNo. 1Under $2 million

Circular Genomics Inc.: Raise no. 1, Aug 2021

Investors in this round

7 investors had bought by the notice of Aug 20, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Hafez · Executive Officer, Director, Promoter
  • Nikolaos Mellios · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alexander Hafez, President. Source: SEC Form D, newest notice filed Aug 20, 2021. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Circular Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2024

That is all the official record says: Circular Genomics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Circular Genomics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Circular Genomics Inc.
NameRoleNamed in
Paul SargeantExecutive officerJan 2024
Alexander HafezExecutive officerMar 2023
Nikolaos MelliosExecutive officerMar 2023
Stephen McKernanExecutive officerMar 2023
David BlivinDirectorJan 2024
Fortunado RoccaDirectorJan 2024
Joseph Cook IIIDirectorJan 2024
Nikolaos MelliosDirectorJan 2024
Paul SargeantDirectorJan 2024
Waneta TuttleDirectorJan 2024
Alexander HafezDirectorMar 2023
Blivin DavidDirectorMar 2023
Cathy PettiDirectorMar 2023
Kosmas KaradimitriouDirectorDec 2021
Alexander HafezPromoterMar 2023
Nikolaos MelliosPromoterMar 2023